Literature DB >> 3873235

Posterior capsular-zonular disruption in planned extracapsular surgery.

F E O'Donnell, B Santos.   

Abstract

The incidence of inadvertent posterior capsule-zonular disruption at each stage of planned extracapsular cataract extraction was studied in a consecutive series of 250 cases. Disruption occurred during nucleus expression in 0.8%, during cortical cleanup in 3.2%, during removal of anterior capsular flaps in 0.4%, during polishing of the posterior capsule in 0.4%, and during posterior chamber lens (Sinskey-style) implantation in 0%. No cases of subluxation of the posterior chamber lens were observed (mean follow-up, 22 months). The overall incidence of posterior capsule-zonular disruption was 4.8%. Vitreous loss occurred in one half of these cases (2.4% of eyes). No cases of dislocation of the nucleus into the vitreous occurred. In 50% of the cases of posterior capsule-zonular disruption (2.4% of eyes), prompt recognition and proper management avoided disruption of the vitreous face. In 80% of these cases with posterior capsule-zonular disruption but intact vitreous face, it was possible to remove sufficient cortex and to proceed with uncomplicated posterior chamber lens implantation.

Entities:  

Mesh:

Year:  1985        PMID: 3873235     DOI: 10.1001/archopht.1985.01050050044013

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Extracapsular cataract extraction with posterior chamber lens implantation in Fuch's heterochromic cyclitis.

Authors:  G S Baarsma; J de Vries; C D Hammudoglu
Journal:  Br J Ophthalmol       Date:  1991-05       Impact factor: 4.638

2.  Proposed classification of lens capsule defects.

Authors:  Zong-Ming Song; Yan-Juan Sheng; Xiao-Ying Fu; An-Quan Xue; Fan Lu; Qin-Mei Wang; Jia Qu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-06-12       Impact factor: 3.117

3.  Continuous curvilinear (circular) capsulorhexis and planned extracapsular cataract extraction--are they compatible?

Authors:  M Pande
Journal:  Br J Ophthalmol       Date:  1993-03       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.